STOCK TITAN
  1. Home
  2. News
  3. BDSX

Biodesix Inc - BDSX STOCK NEWS

Welcome to our dedicated news page for Biodesix (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on Biodesix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biodesix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biodesix's position in the market.

News
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
Rhea-AI Summary
Biodesix, Inc. (BDSX) presented new data at the AACR Annual Meeting 2024 showcasing advancements in liquid biopsy technologies for detecting cell-free DNA and the importance of rapid turnaround time in identifying actionable tumor mutations in a real-world clinical setting. The studies included a presentation on single cell and cell-free nucleic acid analyses using a new droplet digital PCR system, as well as real-world assessment of turnaround time for variant testing in NSCLC. An exploratory analysis from the FLAURA2 clinical study sponsored by AstraZeneca was also presented, focusing on the prognostic and predictive nature of EGFR mutations in patients with EGFR-mutated advanced NSCLC receiving first-line osimertinib treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences
-
News
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
Rhea-AI Summary
Biodesix, Inc. (BDSX) announces the pricing of its underwritten offering of common stock and concurrent private placement, expecting gross proceeds of $55.0 million. The company plans to convert Series A Non-Voting Convertible Preferred Stock to common stock upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.28%
Tags
offering
-
News
Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center
Rhea-AI Summary
Biodesix, Inc. (BDSX) has signed a new master collaborative research agreement with Memorial Sloan Kettering Cancer Center to develop diagnostic tests for cancer treatment. The collaboration aims to create oncology biomarker assays utilizing Biodesix's genomics, proteomics, and data mining capabilities, along with Bio-Rad's digital PCR assay technology. This partnership marks a significant milestone for Biodesix in the field of oncology diagnostics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.35%
Tags
none
News
Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights
Rhea-AI Summary
Biodesix, Inc. (BDSX) reports impressive financial and operational results for the fourth quarter and fiscal year 2023, showcasing significant growth in Lung Diagnostic test volume, gross profit margin improvement, and strong revenue guidance for 2024. The company achieved a 65% increase in Lung Diagnostic test volume in FY2023, with a 77% gross profit margin in Q4 2023. Total revenue for Q4 2023 was $14.7 million, representing a 52% increase year-over-year. Biodesix anticipates generating $65 to $68 million in total revenue in 2024, indicating a 32% to 39% growth rate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
earnings
-
News
Biodesix to Participate in the TD Cowen 44th Annual Health Care Conference
Rhea-AI Summary
Biodesix, Inc. (BDSX) CEO, Scott Hutton, will present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024. The presentation will focus on the company's diagnostic solutions for lung disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
conferences
-
News
Biodesix to Report Fourth Quarter and Full Year 2023 Financial Results on March 1, 2024
Rhea-AI Summary
Biodesix, Inc. (BDSX) will release financial results for Q4 and year-end 2023 on March 1. A conference call and webcast will follow to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.73%
Tags
conferences earnings
News
Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) announced the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing. This method uses the FDA-cleared Tasso+™ device, enabling capillary blood draws for healthcare providers without convenient access to phlebotomy services or licensed phlebotomists. The device was validated to be administered in minutes, creating efficiencies in the Nodify Lung workflow. Biodesix received approval from the New York State Clinical Laboratory Evaluation Program to use the Tasso+ device as a specimen collection method in support of Nodify Lung testing after entering into a supply agreement with Tasso, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
-
News
Biodesix to Participate in Two Upcoming Investor Conferences in November
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) to participate in Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference. CEO Scott Hutton to present and hold 1x1 meetings. Webcast available for replay on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.39%
Tags
conferences
-
News
Biodesix Announces Third Quarter 2023 Results and Highlights
Rhea-AI Summary
BDSX Q3 2023 Financial Results: 60% Lung Diagnostic test volume growth, 76% gross profit margin, $10.9M net loss, and $5.4M Adjusted EBITDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
earnings
News
Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023
Rhea-AI Summary
Biodesix, Inc. (Nasdaq: BDSX) will release financial results for Q3 2023 on November 7. A conference call and webcast will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
conferences earnings
Stock BDSX logo
Biodesix Inc

Nasdaq:BDSX

BDSX Rankings

#4672 Ranked by Market Cap
#548 Ranked by Stock Gains
N/A Ranked by Dividends

BDSX Stock Data

140.63M
39.12M
59.44%
13.73%
0.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United States
Louisville

About BDSX

biodesix develops and commercializes blood-based molecular diagnostic tests that advance the standard of care in oncology. our diagnostics help patients and their doctors make more informed decisions about treatment based on a patient's unique molecular profile. we're advancing precision medicine by helping physicians provide the right patient with the right treatment at the right time, and move patients to optimal treatment faster. we partner with pharmaceutical companies to develop tests that accelerate pipelines and bring effective therapies to market. our two commercialized tests, veristrat® & genestrat™, offer results in 72 hours. no tissue is required.